SRPTSarepta Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Sarepta Therapeutics, Inc. against SPDR S&P Biotech ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SRPT본 종목 | $1.7B#6 | 44.7x#2 | 1.1x#1 | 0.9x#1 | 4.3%#4 | -403.3%#6 | -37.5%#3 | -47.4%#3 | -67.2%#1 | — | -1.5%#2 | — |
| INSM | $21.4B#2 | — | 30.4x#5 | 35.4x#4 | 66.7%#2 | -39.7%#3 | -205.6%#4 | -181.1%#5 | -185.1%#2 | 4#1 | — | — |
| SMMT | $10.4B#3 | — | 16.6x#4 | — | — | -387.8%#5 | — | -171.4%#4 | — | — | — | — |
| UTHR | $21.9B#1 | 19.1x#1 | 3.7x#2 | 6.9x#3 | 10.6%#3 | 11.7%#2 | 46.9%#2 | 22.6%#1 | — | — | — | — |
| PRAX | $8.5B#4 | — | 6.0x#3 | — | -100.0%#5 | -65.6%#4 | — | -21.5%#2 | — | — | — | — |
| PTCT | $5.7B#5 | — | — | 3.3x#2 | 114.5%#1 | 288.0%#1 | 50.1%#1 | — | — | — | 30.8%#1 | — |
Peer set: top holdings of XBI (SPDR S&P Biotech ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-08-03.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice